Neuphoria Therapeutics (NEUP) Change in Receivables (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Change in Receivables of $495432.0 for Q1 2026, up 4616.66% year-over-year from $10503.9 in Q1 2025, and down 55.29% quarter-over-quarter from $1.1 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Change in Receivables (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Change in Receivables for 4 consecutive years, with $495432.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 4616.66% year-over-year to $495432.0; the TTM figure through Mar 2026 stood at $1.6 million (up 2048.77% YoY), while the FY2025 annual figure was -$114936.0, up 61.59% from the prior year.
- Change in Receivables declined to $495432.0 in Q1 2026 per NEUP's latest filing, from $1.1 million in the prior quarter.
- Across five years, Change in Receivables topped out at $1.1 million in Q4 2025 and bottomed at -$326992.0 in Q4 2023.
- Historically, Change in Receivables has averaged $107204.8 across 4 years, with a median of -$10190.0 in 2025.
- Annual changes were most pronounced in 2024 — Change in Receivables slumped 167.22% — and 2026, when it jumped 4616.66%.
- Neuphoria Therapeutics' Change in Receivables stood at -$326992.0 in 2023, then surged by 75.41% to -$80399.0 in 2024, then surged by 1478.31% to $1.1 million in 2025, then slumped by 55.29% to $495432.0 in 2026.
- Business Quant data shows NEUP's Change in Receivables at $495432.0 in Q1 2026, $1.1 million in Q4 2025, and -$10190.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 31.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 37.16 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 94.29 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 495,432.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 495,432.00 |
| Mar 31, 2026 | 495,432.00 |
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | -10,190.00 |
| Sep 30, 2025 | -10,190.00 |
| Jun 30, 2025 | -12,644.00 |
| Jun 30, 2025 | -12,644.00 |
| Mar 31, 2025 | -10,969.00 |
| Mar 31, 2025 | -10,969.00 |
| Dec 31, 2024 | -80,399.00 |
| Dec 31, 2024 | -80,399.00 |
| Sep 30, 2024 | -10,924.00 |
| Sep 30, 2024 | -10,924.00 |
| Jun 30, 2024 | 21,177.00 |
| Jun 30, 2024 | 21,177.00 |
| Mar 31, 2024 | -9,640.00 |
| Mar 31, 2024 | -9,640.00 |
| Dec 31, 2023 | -326,992.00 |
| Dec 31, 2023 | -326,992.00 |